Key result
Ticagrelor achieved lower platelet reactivity compared with prasugrel in ACS patients with diabetes.
Why the study?
Does ticagrelor improve platelet inhibition compared to prasugrel in ACS patients with diabetes mellitus undergoing PCI?
RCT (n=30)
Single-blind
Randomized crossover
No
Does ticagrelor improve platelet inhibition compared to prasugrel in ACS patients with diabetes mellitus undergoing PCI?
Ticagrelor provides significantly greater platelet inhibition than prasugrel in diabetic patients with ACS undergoing PCI, though both agents effectively overcome high platelet reactivity.
Answers are grounded in this paper and cite their sources.
Supports ticagrelor preference for stronger platelet inhibition in diabetic ACS undergoing PCI; extends randomized PD data to this high-risk subgroup.
OBJECTIVE: It has been postulated that prasugrel might be the preferred treatment option in diabetes mellitus (DM) patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). We aimed to compare the pharmacodynamic action of ticagrelor versus prasugrel. RESEARCH DESIGN AND METHODS: In a prospective, single-center, single-blind, crossover study, 30 consecutive ACS patients with DM who had been pretreated with clopidogrel were randomized to either 90 mg ticagrelor twice daily or 10 mg prasugrel once daily with a 15-day treatment period. Platelet reactivity (PR) was assessed with the VerifyNow P2Y12 function assay, measured in P2Y12 reaction units (PRU). RESULTS: PR was significantly lower after ticagrelor (45.2 PRU [95% CI 27.4-63.1]) compared with prasugrel (80.8 PRU [63.0-98.7]), with a least squares mean difference of -35.6 PRU (-55.2 to -15.9, P = 0.001). High PR rate was 0% for ticagrelor and 3.3% for prasugrel (P = 1.0). CONCLUSIONS: In DM patients with ACS who had been pretreated with clopidogrel and who undergo PCI, ticagrelor achieves a significantly higher platelet inhibition than prasugrel. Both antiplatelet agents effectively treat high PR. The relevance of these findings to the clinical efficacy and safety of ticagrelor and prasugrel in DM patients needs further elucidation.
No takes yet. Share an insight, caveat, or question.
Alexopoulos et al. (2013) conducted an RCT in Acute coronary syndrome with diabetes mellitus (n=30). Ticagrelor vs. Prasugrel 10 mg once daily was evaluated on Platelet reactivity (PR) measured in P2Y12 reaction units (PRU) (MD -35.6, 95% CI -55.2 to -15.9, p=0.001). Ticagrelor achieved lower platelet reactivity compared with prasugrel in ACS patients with diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: